ELISA/assay

Mouse Apolipoprotein A1 ELISA Kit

MBS733356

48-Strip-Wells

470 USD

ELISA Kit

Mouse Apolipoprotein A1 ELISA Kit

Apolipoprotein A1

apolipoprotein A-I preproprotein; Apolipoprotein A-I; apolipoprotein A-I; apo-AI; apolipoprotein A-I; Apolipoprotein A1Cleaved into the following 2 chains:Proapolipoprotein A-I; ProapoA-I; Truncated apolipoprotein A-IAlternative name(s):Apolipoprotein A-I(1-242)

APOA1

APOA1; APOA1; Apo-AI; ApoA-I; ProapoA-I

APOA1_HUMAN

Mouse

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive

Intended Uses: This Apo-AI ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Mouse Apo-AI. This ELISA kit for research use only, not for therapeutic or diagnostic applications. !Intended Uses: This Apo-AI ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Mouse Apo-AI. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cardiovascular

Principle of the Assay: Apo- AI ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti- Apo-AI antibody and an Apo-AI-HRP conjugate. The assay sample and buffer are incubated together with Apo-AI-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the Apo-AI concentration since Apo-AI from samples and Apo-AI-HRP conjugate compete for the anti-Apo-AI antibody binding site. Since the number of sites is limited, as more sites are occupied by Apo-AI from the sample, fewer sites are left to bind Apo-AI-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The Apo-AI concentration in each sample is interpolated from this standard curve.

4557321

NP_000030.1

NM_000039.1

30,778 Da

ABC-family Proteins Mediated Transport Pathway (106573); ABCA Transporters In Lipid Homeostasis Pathway (477112); African Trypanosomiasis Pathway (194384); African Trypanosomiasis Pathway (194323); Amyloids Pathway (366238); Binding And Uptake Of Ligands By Scavenger Receptors Pathway (771599); Chylomicron-mediated Lipid Transport Pathway (106157); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); FOXA2 And FOXA3 Transcription Factor Networks Pathway (137911)

This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. [provided by RefSeq, Jul 2008]

APOA1: Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. Interacts with APOA1BP and CLU. Component of a sperm activating protein complex (SPAP), consisting of APOA1, an immunoglobulin heavy chain, an immunoglobulin light chain and albumin. Interacts with NDRG1. Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease. Belongs to the apolipoprotein A1/A4/E family. Protein type: Lipid-binding; Secreted, signal peptide; Secreted; Vesicle; Endoplasmic reticulum; Cell development/differentiation; Motility/polarity/chemotaxis. Chromosomal Location of Human Ortholog: 11q23-q24. Cellular Component: extracellular space; chylomicron; cell surface; endoplasmic reticulum lumen; endocytic vesicle; early endosome; extracellular region; plasma membrane; cytoplasmic vesicle; nucleus; cytosol; vesicle. Molecular Function: identical protein binding; lipase inhibitor activity; beta-amyloid binding; cholesterol binding; phosphatidylcholine binding; high-density lipoprotein binding; protein binding; enzyme binding; phospholipid transporter activity; chemorepellent activity; cholesterol transporter activity; phospholipid binding; apolipoprotein A-I receptor binding; apolipoprotein receptor binding. Biological Process: phototransduction, visible light; negative chemotaxis; negative regulation of lipase activity; axon regeneration in the peripheral nervous system; sequestering of lipid; negative regulation of interleukin-1 beta secretion; regulation of cholesterol absorption; transforming growth factor beta receptor signaling pathway; positive regulation of stress fiber formation; response to drug; platelet activation; cholesterol metabolic process; organ regeneration; regulation of Cdc42 protein signal transduction; adrenal gland development; positive regulation of hydrolase activity; positive regulation of Rho protein signal transduction; lipoprotein metabolic process; positive regulation of transferase activity; vitamin transport; cholesterol biosynthetic process; negative regulation of cytokine secretion during immune response; cholesterol homeostasis; lipoprotein biosynthetic process; response to estrogen stimulus; peptidyl-methionine modification; phosphatidylcholine biosynthetic process; positive regulation of lipoprotein lipase activity; blood vessel endothelial cell migration; cellular lipid metabolic process; platelet degranulation; phospholipid efflux; retinoid metabolic process; transmembrane transport; response to nutrient; phospholipid homeostasis; integrin-mediated signaling pathway; receptor-mediated endocytosis; positive regulation of fatty acid biosynthetic process; regulation of protein amino acid phosphorylation; cholesterol transport; protein stabilization; protein amino acid oxidation; negative regulation of heterotypic cell-cell adhesion; neurite regeneration; cholesterol efflux; glucocorticoid metabolic process; G-protein coupled receptor protein signaling pathway; reverse cholesterol transport; endothelial cell proliferation; negative regulation of inflammatory response; blood coagulation. Disease: Hypoalphalipoproteinemia, Primary; Amyloidosis, Familial Visceral

48-Strip-Wells

470 USD

96-Strip-Wells

675